Please ensure Javascript is enabled for purposes of website accessibility
Mark Prvulovic

Mark Prvulovic


Before joining The Motley Fool, Mark worked as a freelance financial writer covering a variety of markets. Now he spends most of his time researching promising biotech and cannabis stocks, but from time to time will write about whatever catches his interest no matter the industry.

Recent articles

marijuana plant cash

3 Reasons I'm Cautious About Canopy Growth Stock

Not all is rosy for this cannabis giant. Here are a few things you should keep in mind about Canopy.

COVID-19 vaccine vial

Is Now the Right Time to Buy Novavax Stock?

Following strong clinical data from its COVID-19 vaccine, shares of Novavax are trading at record highs.

rising stock arrow pharma

3 Pharmaceutical Stocks That Can Make You Rich

Some of the most promising stocks on the market right now are pharmaceuticals.


Is Aimmune Therapeutics a Buy?

Is this battered biotech stock now a good deal for investors?

stock arrow downwards 2

What Should Investors Think of Aphria's Unexpected Quarterly Loss?

This once-profitable cannabis company reported a $99 million net loss. Is this a bad sign of things to come?

coronavirus 7

Is BioCryst Pharmaceuticals Stock a Buy?

Forget its coronavirus treatment, berotralstat could be BioCryst's next blockbuster drug.

cannabis oil 1

Should Investors Buy GW Pharma Stock Right Now?

Wall Street analysts think this stock could double. Are they right?

COVID-19 vial stock market

The 1 Promising Coronavirus Stock No One Knows About Yet

Kamada might be the least well-known biotech company working on a COVID-19 treatment right now.

2020 coins savings

3 Safe and Cheap Dividend Stocks to Buy

You'll be surprised at just how much some of these companies pay out in dividends.


5 Winning Stocks That Will Continue to Thrive in 2020

From gold miners to vaccine developers, these companies have been killing it so far this year.

stethoscope market up

Could This Obscure Biotech Stock Make You a Fortune?

Two major catalysts on the horizon could send Omeros' stock soaring. What should investors think?

marijuana plant

3 Pot Stocks That Could Become Big Winners in 2020

These cannabis companies have a lot of good things going for them right now. Here's why.

vet and dog

Is Elanco Stock a Buy?

Despite mediocre financial results, could a major upcoming acquisition be what this company needs to succeed?


Is Canopy Growth at Risk of Going Bankrupt?

Should investors be worried about this pot industry giant going out of business?

person money growing

Could This Obscure Biotech Stock Make Early Investors a Fortune?

If you haven't heard of Akero Therapeutics before, take note. Its NASH drug candidate could be a game changer.


Is Natus Medical Stock a Buy?

What should investors think of this infant care and neurology specialist?


Is Teva Pharmaceuticals Stock a Buy?

Is the company's cheap price worth its debt load?

COVID vaccine dollars bills

Fauci Just Singled Out This Biotech Stock. Is It a Buy?

Out of all the coronavirus vaccine makers on the market, why did Dr. Anthony Fauci call out Moderna?

stock arrow up blue background

4 Promising Stocks to Own That You Probably Forgot About

These four companies have tremendous growth potential going into 2020.

cannabis plant 2

Is Aurora Cannabis Finally Making a Recovery?

Are better-than-expected financial results enough to make this recovering pot stock a buy?